Predictors of Aspirin Nonadherence in Adults With Prior Myocardial Infarction.

Crit Pathw Cardiol

From the Division of Cardiology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY.

Published: September 2020

Background: Medication nonadherence is an alarming public health concern due to its effect on both individual treatment success and overall health care costs. This study sought to identify the predictors of aspirin nonadherence in adults with prior myocardial infarction (MI).

Methods: The 2017 Centers for Disease Control's Behavioral Risk Factor Surveillance Survey, a nationally representative, cross-sectional survey, was utilized to identify a cohort of community-dwelling adults (age ≥ 18 years) with prior MI (n = 2173). The primary outcome of interest was presence of self-reported aspirin nonadherence.

Results: Among 2173 participants with prior MI studied, a total of 550 participants (25.3%) reported aspirin nonadherence, whereas 1623 participants (74.7%) reported adherence to aspirin. Adults with aspirin nonadherence were younger and more likely to be female, Black, and of Hispanic ethnicity. They also had lower annual income and were less likely to have health insurance or own a home. Participants with aspirin nonadherence had less frequent medical checkups and lower rates of multiple comorbidities including diabetes mellitus, hypertension, hyperlipidemia, and obesity. In multivariable analysis, independent predictors of aspirin nonadherence included female sex [odds ratio (OR), 1.42; 95% confidence interval (CI), 1.14-1.83], Black race (OR, 1.64; 95% CI, 1.19-2.26), Hispanic ethnicity (OR, 2.27; 95% CI, 1.60-3.21), current employment (OR, 1.74; 95% CI, 1.28-2.36), and absence of homeowner status (OR, 0.71; 95% CI, 0.55-0.93).

Conclusions: In this observational contemporary study of adults with prior MI, predictors of aspirin nonadherence included female sex, Black race, Hispanic ethnicity, currently employed status, and absence of homeowner status.

Download full-text PDF

Source
http://dx.doi.org/10.1097/HPC.0000000000000218DOI Listing

Publication Analysis

Top Keywords

aspirin nonadherence
28
predictors aspirin
16
adults prior
12
hispanic ethnicity
12
nonadherence
8
nonadherence adults
8
prior myocardial
8
myocardial infarction
8
aspirin
8
nonadherence included
8

Similar Publications

Objectives: To evaluate the impact of aspirin resistance on the incidence of preeclampsia and maternal serum biomarker levels in pregnant individuals at high-risk of preeclampsia receiving low dose aspirin (LDA).

Study Design: We performed a secondary analysis of a randomized, placebo-controlled trial of LDA (60 mg daily) for preeclampsia prevention in high-risk individuals (N = 524) on pregnancy outcomes and concentrations of PLGF, IL-2, IL-6, thromboxane B2 (TXB), sTNF-R1 and sTNF-R2 from maternal serum.

Main Outcome Measures: LDA-resistant individuals were defined as those having a TXB concentration >10 ng/ml or <75 % reduction in concentration at 24-28 weeks after LDA administration.

View Article and Find Full Text PDF

Barriers to Antiplatelet and Statin Adherence Following Major Vascular Intervention.

Ann Vasc Surg

September 2024

The University of Arizona College of Medicine - Tucson, Tucson, AZ; Division of Vascular Surgery and Endovascular Therapy, The University of Arizona Department of Surgery, Tucson, AZ. Electronic address:

Background: Antiplatelets and statins therapies are associated with improved cardiovascular outcomes following major vascular intervention. Many vascular surgery institutions are reporting improved prescribing rates for aspirin (ASA), P2Y12 antagonists, and statins. Nevertheless, there remains limited publication describing rates and patient-perceived barriers for postoperative adherence.

View Article and Find Full Text PDF

The aim of this study was to determine the rate of aspirin responsiveness in a cohort of pediatric patients with in situ xenograft valved right ventricle to pulmonary artery (RV-PA) conduits and/or transcatheter valve replacements (TVR). Aspirin is routinely prescribed to these patients. Optimizing anti-platelet therapy could promote valve longevity and reduce the risk of infective endocarditis in this at-risk group.

View Article and Find Full Text PDF

Aims: Aspirin is considered mandatory after myocardial infarction (MI). However, its long-term efficacy has been questioned. This study investigated the effectiveness of long-term aspirin after MI.

View Article and Find Full Text PDF

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

JACC Cardiovasc Interv

October 2023

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:

Background: Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases.

Objectives: The authors sought to evaluate the incidence, predictors, and outcomes of dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention (PCI).

Methods: In the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, patients were maintained on ticagrelor and randomized to aspirin or placebo for 1 year.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!